Osteoporosis in multiple sclerosis
- PMID: 20551086
- DOI: 10.1177/1352458510368985
Osteoporosis in multiple sclerosis
Abstract
Fractures resulting from osteoporosis are a major cause of morbidity and mortality in the developed world. People with multiple sclerosis experience reduced mobility and are susceptible to falls. Glucocorticoid use and reduced mobility are known risk factors for osteoporosis. This paper is a review of osteoporosis in people with multiple sclerosis, looking at its prevalence, risk factors and possible mechanisms. We also review management guidelines for osteoporosis in the general population and use these to propose guidelines for osteoporosis management amongst multiple sclerosis patients. A number of studies have examined the incidence of reduced bone mineral density amongst people with multiple sclerosis; the majority provide convincing evidence that bone mineral density is significantly reduced in multiple sclerosis patients. The most significant risk factors appear to arise from the chronic disease process of multiple sclerosis and not from glucocorticoid use. There are currently no guidelines or consensus as how best to treat osteoporosis amongst multiple sclerosis patients despite their being at an increased risk. We propose an algorithm for the screening and treatment of osteoporosis in people with multiple sclerosis.
Similar articles
-
Primary care use of FRAX: absolute fracture risk assessment in postmenopausal women and older men.Postgrad Med. 2010 Jan;122(1):82-90. doi: 10.3810/pgm.2010.01.2102. Postgrad Med. 2010. PMID: 20107292 Review.
-
Bone health and multiple sclerosis.Mult Scler. 2012 Nov;18(11):1522-8. doi: 10.1177/1352458512453362. Epub 2012 Jun 27. Mult Scler. 2012. PMID: 22740489 Review.
-
Screening for osteoporosis in the adult U.S. population: ACPM position statement on preventive practice.Am J Prev Med. 2009 Apr;36(4):366-75. doi: 10.1016/j.amepre.2009.01.013. Am J Prev Med. 2009. PMID: 19285200 Review.
-
Assessment of fracture risk key in osteoporosis.Practitioner. 2008 Dec;252(1713):15-6, 19. Practitioner. 2008. PMID: 19192698 No abstract available.
-
[Bone and calcium update; diagnosis and therapy of metabolic bone disease update. Guideline for prevention and treatment of osteoporosis update].Clin Calcium. 2011 Dec;21(12):123-43. Clin Calcium. 2011. PMID: 22133832 Review. Japanese.
Cited by
-
High-Dose Intravenous Steroid Treatment Seems to Have No Long-Term Negative Effect on Bone Mineral Density of Young and Newly Diagnosed Multiple Sclerosis Patients: A Pilot Study.Biomedicines. 2023 Feb 17;11(2):603. doi: 10.3390/biomedicines11020603. Biomedicines. 2023. PMID: 36831140 Free PMC article.
-
Propionic acid beneficially modifies osteoporosis biomarkers in patients with multiple sclerosis.Ther Adv Neurol Disord. 2022 Jun 21;15:17562864221103935. doi: 10.1177/17562864221103935. eCollection 2022. Ther Adv Neurol Disord. 2022. PMID: 35755968 Free PMC article.
-
Impact of aging on treatment considerations for multiple sclerosis patients.Front Neurol. 2023 Jul 7;14:1197212. doi: 10.3389/fneur.2023.1197212. eCollection 2023. Front Neurol. 2023. PMID: 37483447 Free PMC article. Review.
-
Vitamin D receptor Bsm1 polymorphism, calcium metabolism and bone mineral density in patients with multiple sclerosis: a pilot study.Neurol Sci. 2013 Aug;34(8):1433-9. doi: 10.1007/s10072-012-1259-7. Epub 2012 Dec 5. Neurol Sci. 2013. PMID: 23212404
-
The Brain-Gut-Bone Axis in Neurodegenerative Diseases: Insights, Challenges, and Future Prospects.Adv Sci (Weinh). 2024 Oct;11(38):e2307971. doi: 10.1002/advs.202307971. Epub 2024 Aug 9. Adv Sci (Weinh). 2024. PMID: 39120490 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical